<DOC>
	<DOCNO>NCT00090103</DOCNO>
	<brief_summary>This study investigate efficacy safety treatment dutasteride tamsulosin , administer daily 4 year , alone combination , improvement symptom clinical outcome men moderate severe symptomatic Benign Prostatic Hyperplasia ( BPH ) . Study visit every 3 month 4 year ( 18 clinic visit ) . Transrectal ultrasound ( TRUS ) do annually .</brief_summary>
	<brief_title>Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment</brief_title>
	<detailed_description>A randomised , double-blind , parallel group study investigate efficacy safety treatment Dutasteride ( 0.5 mg ) Tamsulosin ( 0.4 mg ) , administer daily 4 year , alone combination , improvement symptom clinical outcome men moderate severe symptomatic benign prostatic hyperplasia .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>Inclusion criterion : A subject consider eligible inclusion study follow criterion apply : male , age ≥50 year clinical diagnosis BPH medical history physical examination , include digital rectal examination ( DRE ) International Prostate Symptom Score ( IPSS ) ≥12 point Screening prostate volume ≥30 cc transrectal ultrasonography ; ( TRUS ) total serum Prostate Specific Antigen ( PSA ) ≥1.5ng/mL Screening maximum flow rate ( Qmax ) &gt; 5 mL/sec ≤15 mL/sec minimum void volume ≥125 mL Screening ( base two void ) willing able give write informed consent comply study procedure fluent literate local language ability read , comprehend record information IPSS , BII Patient Perception Study Medication able swallow retain oral medication willing able participate study full 4 year . A subject eligible inclusion study follow criterion apply : total serum PSA &gt; 10.0ng/mL Screening history evidence prostate cancer ( e.g . positive biopsy ultrasound , suspicious DRE ) . Patients suspicious ultrasound DRE negative biopsy within precede 6 month stable PSA eligible study . Note : If total serum PSA &gt; 4ng/mL unless PSA value stable least past 2 year , investigator make every appropriate effort exclude possibility prostate cancer , e.g . DRE , review TRUS take within previous month , consider 812 core prostate biopsy accordance routine clinical practice . previous prostatic surgery ( include TURP , balloon dilatation , thermotherapy stent replacement ) invasive procedure treat BPH . history flexible/rigid cystoscopy instrumentation urethra within 7 day prior Screening Visit . Routine catheterisation acceptable time restriction . history AUR within 3 month prior Screening Visit . postvoid residual volume &gt; 250mL ( suprapubic ultrasound ) Screening . cause BPH , may judgement investigator , result urinary symptom change flow rate ( e.g . neurogenic bladder , bladder neck contracture , urethral stricture , bladder malignancy , acute chronic prostatitis , acute chronic urinary tract infection ) . history breast cancer clinical breast examination find unclear origin suggestive malignancy . use 5alphareductase inhibitor ( e.g . Proscar® , Propecia® , Avodart® ) , drug antiandrogenic property ( e.g . spironolactone , flutamide , bicalutamide , cimetidine , ketoconazole , metronidazole , progestational agent ) , drug affect prostate volume , within past 6 month Screening Visit throughout study ( study medication ) . concurrent use anabolic steroid use phytotherapy BPH within 2 week Screening Visit and/or predict need phytotherapy study . use alphaadrenoreceptor blocker ( i.e . indoramin , prazosin , terazosin , tamsulosin , alfuzosin doxazosin ) within 2 week Screening Visit and/or predict need alpha blocker tamsulosin study . Note : purpose criterion able standardise baseline symptom severity enrol patient prior randomisation specifically exclude current alphaadrenoreceptor blocker user participation study . use alphaadrenoreceptor agonist ( e.g . pseudoephedrine , phenylephrine , ephedrine ) anticholinergic ( e.g . oxybutynin , propantheline ) cholinergics ( e.g . bethanecol chloride ) within 48 hour prior uroflowmetry assessment . hypersensitivity alpha/beta adrenoreceptor blocker 5alphareductase inhibitor , chemicallyrelated drug . concurrent use drug know thought interaction tamsulosin , e.g . cimetidine warfarin . history hepatic impairment abnormal liver function test Screening defined alanine aminotransferase ( ALT ) , aspartate aminotranferase ( AST ) , and/or alkaline phosphatase &gt; 2 time upper limit normal , total bilirubin &gt; 1.5 time upper limit normal ( unless associate predominantly indirect bilirubin elevation Gilbert 's syndrome ) . history renal insufficiency , serum creatinine &gt; 1.5 time upper limit normal serum creatinine ≥1.5 mg/dL Screening . prior history malignancy basal cell carcinoma squamous cell carcinoma skin within past 5 year . Subjects prior malignancy evidence disease least past 5 year eligible . history illness opinion investigator might confound result study pose additional risk patient . unstable , serious coexist medical condition ( ) include , limited , myocardial infarction , coronary bypass surgery , unstable angina , cardiac arrhythmia , clinically evident congestive heart failure , cerebrovascular accident within 6 month prior Screening visit ; uncontrolled diabetes peptic ulcer disease uncontrolled medical management . history postural hypotension , dizziness , vertigo sign symptom orthostasis , opinion investigator could exacerbate tamsulosin result put subject risk injury . history unsuccessful treatment tamsulosin 'first dose ' hypotensive episode initiation alpha1adrenoreceptor antagonist therapy . history unsuccessful treatment finasteride dutasteride history current evidence drug alcohol abuse within previous 12 month . participation investigational market drug trial within 30 day ( 5 halflives whichever longer ) precede Screening Visit and/or course study .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Combination Therapy</keyword>
	<keyword>dutasteride</keyword>
	<keyword>BPH</keyword>
</DOC>